SAN DIEGO, CA -- Dr. Yoav Medan, Vice President and Chief Systems Architect at InSightec Ltd., today presented a startling vision of the operating room of the future at the 2011 TEDMED conference here.
“The dream of Star Trek's Dr. McCoy -- practicing surgery without opening the patient -- is closer to reality than you might think,” Dr. Medan told an audience of more than 800 leaders from medical and non-medical fields.
Dr. Medan showcased the groundbreaking technology of MR guided Focused Ultrasound, pioneered by InSightec. This innovative non-invasive surgical technique employs high-intensity, focused ultrasound waves.
View Medan's talk at TEDMED.
According to InSightec, Focused Ultrasound has huge potential to treat a wide variety of medical problems -- including many diseases for which no effective solutions currently exist.
TEDMED, is the annual conference where cutting-edge science and technology leaders "connect, understand and inspire" to advance the art of health and medicine with new ideas, the latest science and innovative technology.
TEDMED is the only independent licensee of the famous TED conference, the platform for talks that have been downloaded 500 million times around the world.
“Clinical research has shown the potential to destroy tumors without surgery and without ionizing radiation, potentially reducing the adverse effects usually associated with these types of treatments,” said Dr. Medan. “The marriage of MRI and focused ultrasound provides precise visualization of the anatomy, treatment guidance and thermal feedback. This has enabled us to bring this technology into clinical use for uterine fibroids with over 7,000 patients treated. Published papers report dozens of babies who have been born to mothers who underwent FUS for fibroid treatment.”
Some 1,000 patients have also been treated worldwide as part of clinical investigations for painful bone metastases, prostate, liver and breast cancer and 30 patients have been treated for essential tremor, Parkinson’s disease and neuropathic pain with very promising results.
Because this outpatient procedure is non-invasive, patients report that they quickly resume their normal lives and activities.
“Beyond its potential to treat disease or relieve symptoms of disease," Medan stressed, "patients have provided testimony that Focused Ultrasound offers them and their families something almost as important: improved quality of life. It has a transformative impact."
Dr. Medan is responsible for developing new platforms for InSightec’s Magnetic Resonance Guided Focused Ultrasound technology. The holder of two dozen patents, he also mentors young entrepreneurs.
Dr. Medan will be spending the 2012 academic year developing a new medical device research initiative at the Technion, Israel Institute of Technology .
Dr. Medan received his D.Sc. and B.Sc. (Summa Cum Laude) in Aeronautical Engineering from the Technion, Israel Institute of Technology, and an M.B.A from Bradford University, UK.
InSightec Ltd. is a privately held company owned by Elbit Imaging, General Electric, MediTech Advisors, LLC and employees. It was founded in 1999 to develop the breakthrough MR guided Focused Ultrasound technology and transform it into the next generation operating room. Headquartered near Haifa, Israel, the company has over 130 employees and has invested more than $150 million in research, development, and clinical investigations. Its U.S. headquarters are located in Dallas, Texas. For more information, please go to: http://www.insightec.com/
The ExAblate is the first product to use the MR guided focused ultrasound technology that combines MRI -- to visualize the body anatomy, plan the treatment and monitor treatment outcome in real time -- and high intensity focused ultrasound to thermally ablate tumors inside the body non-invasively. MR thermometry, provided uniquely by the system, allows the physician to control and adjust the treatment in real time to ensure that the targeted tissue is treated and surrounding non targeted tissue is spared. The ExAblate system received the European CE mark for uterine fibroids in 2002, for pain palliation of bone metastases in June 2007 and for adenomyosis in June 2010. It was approved by the U.S. Food and Drug Administration in 2004 for symptomatic uterine fibroids. Over 8,000 patients have been treated worldwide with ExAblate systems.